Key result
Thrombin induced a 9.6-fold increase in endothelial monolayer permeability, which was inhibited by cAMP-elevating agents, suggesting intracellular cAMP mediates permeability barrier function.
Why the study?
Do vasoactive agonists and intracellular cAMP alter the permeability of human endothelial monolayers?
Do vasoactive agonists and intracellular cAMP alter the permeability of human endothelial monolayers?
Intracellular cAMP plays a key mediating role in maintaining the permeability barrier function of human endothelial monolayers and protecting against thrombin-induced hyperpermeability.
Answers are grounded in this paper and cite their sources.
May guide endothelial research; hypothesis-generating and requires human validation before any clinical consideration.
Permeability coefficients of human umbilical vein endothelial cell monolayers cultured on polycarbonate filters were determined by monitoring transendothelial albumin transport. Permeability was determined as a function of time in culture and in the presence of vasoactive agonists. Permeability decreased with increasing time in culture. All agonist experiments were performed with 15-day cultures because this time point best modeled the in vivo permeability barrier function. Permeability of endothelial monolayers decreased significantly in the presence of the stable prostacyclin analogue iloprost (6 nM), dibutyryl adenosine 3',5'-cyclic monophosphate (cAMP, 0.5 mM)-3-isobutyl-1-methylxanthine (IBMX, 0.1 mM), 8-bromo cAMP (0.5 mM)-IBMX, dibutyryl cAMP-theophylline (0.5 mM), or IBMX. A 9.6-fold increase in permeability resulting from thrombin [0.15 U/ml (1 nM)] treatment was inhibited by pretreating the monolayers with dibutyryl cAMP-IBMX, 8-bromo cAMP-IBMX, dibutyryl cAMP-theophylline, dibutyryl cAMP, IBMX, iloprost, or D-Phe-Pro-Arg-CH2-alpha-thrombin (1 nM). The thrombin-induced permeability increase was not significantly altered by pretreating monolayers with aspirin (5 microM) or indomethacin (50 microM). Inactivated forms of thrombin, diisopropylflurophosphate-alpha-thrombin (1 nM) and D-Phe-Pro-Arg-CH2-alpha-thrombin, did not significantly affect permeability. Monolayer permeability was not altered in response to bradykinin (1 microM). These results suggest a mediating role for intracellular cAMP in the permeability barrier function of endothelial monolayers.
No takes yet. Share an insight, caveat, or question.
Casnocha et al. (1989) studied this question. Vasoactive agonists and cAMP-elevating agents was evaluated on Permeability of endothelial monolayers (9.6-fold increase with thrombin). Thrombin induced a 9.6-fold increase in endothelial monolayer permeability, which was inhibited by cAMP-elevating agents, suggesting intracellular cAMP mediates permeability barrier function.
Synapse has enriched 10 related papers. Consider them for comparative context: